Clinical Trial Update: Use of Tacrolimus and MTOR Inhibitors With Anticipatory Therapy vs. Tacrolimus and Mycophenolic Acid With Universal Prophylaxis in Renal Recipients at High Risk of Posttransplant Cytomegalovirus. [Phase 4]

View source ↗

Summary

Phase 4 trial in high-risk kidney transplant recipients evaluating CMV prevention strategies: tacrolimus-based regimens with anticipatory therapy and mTOR inhib…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infections

Drugs mentioned

• Everolimus (everolimus)
• Mycophenolate mofetil (CellCept) (mycophenolate mofetil)
• Sirolimus (Rapamycin) (sirolimus)
• Tacrolimus (Tacrolimus)

Snippet

Sponsor: Hospital Universitario La Paz | Conditions: Evaluate the Effectiveness of CMV Prevention Strategies in Kidney Transplant Recipients | Phase 4 | Status: NOT_YET_RECRUITING